Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors 2019
2019 Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment 2019
2017 Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score 2017
2017 A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma 2017
2017 Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer 2017
2017 Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer 2017
2017 Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study 2017
2016 Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients 2016
2015 Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC) 2015
2014 An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer 2014
2014 EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324 2014
2014 Endoglin for targeted cancer treatment topical collection on evolving therapies 2014
2013 Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial 2013
2012 Leukaemia cutis 2012
2012 Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: A lead-in study 2012
2011 Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 2011
2011 Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer 2011
2010 Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. 2010
2010 The potential benefits of low-molecular-weight heparins in cancer patients 2010
2010 A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer 2010
2009 Vorinostat in solid and hematologic malignancies 2009
2009 A novel five-antibody immunohistochemical test for subclassification of lung carcinoma 2009
2009 Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy 2009
2008 Non-small cell lung cancer 2008
2008 Small cell lung cancer 2008
2007 A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer Scheduled to Receive First-Line Chemotherapy 2007
2006 Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer 2006
2006 Non-small cell lung cancer: Clinical Practice Guidelines in Oncology™ 2006
2006 Small cell lung cancer: Clinical Practice Guidelines in Oncology™ 2006
2006 Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men 2006
2005 Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer 2005
2005 Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration 2005
2005 Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer 2005
2005 Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer 2005
2004 Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936 2004
2003 Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: Preliminary results 2003
2003 Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: Clinical effects and hematologic toxicity 2003
2003 Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy 2003
2002 Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy 2002
2002 Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: Long-term follow-up of a phase I trial 2002
2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer 2001
2000 A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer 2000
1999 Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer 1999
1999 Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy m locally advanced non-small cell lung cancer: Analysis of early and late pulmonary morbidity 1999
1997 A Phase II study of topotecan in patients with recurrent head and neck cancer: Identification of an active new agent 1997
1997 Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and leukemia group B study 9022 1997
1996 Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer 1996
1996 Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer 1996
1994 Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer 1994
1993 Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer 1993
1993 Hemostatic abnormalities associated with monoclonal gammopathies 1993
1992 A phase II trial of CI-921 in advanced malignancies 1992
1992 Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck 1992
1988 Lupus anticoagulant and Waldenstrom's macroglobulinemia. 1988
1988 Effect of mopidamol on survival in carcinoma of the lung and colon: Final report of veterans administration cooperative study no. 188 1988
1988 Trimetrexate as a single agent in patients with advanced head and neck cancer 1988
1988 Trimetrexate combined with cisplatin or etoposide in the treatment of nonsmall cell lung cancer: A pilot study 1988
1985 Phase II trial of diaziquone in patients with colon cancer 1985
1984 Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: A Southeastern Cancer Study Group trial 1984
1981 Radionuclide angiography: Superior vena caval obstruction 1981
1981 Randomized comparison of cyclophosphamide (C), adriamycin (A), methotrexate (M) and folinic acid (F) vs cyclophosphamide, adriamycin and cis-platinum (P) vs cyclophosphamide and adriamycin in advanced non small cell lung cancer (NSCLC) 1981
1980 Hairy cell leukemia. Case report and review of the literature. 1980
1980 Combination chemotherapy with cyclophosphamide, adriamycin, intermediate dose methotrexate, and folinic acid rescue (CAMF) in advanced lung cancer 1980
1979 Serum concentration of methotrexate (MTX) during high, intermediate and low dosage schedules 1979
1978 Recent advances in the management of aplastic anemia: a clinical review and case report. 1978
1977 Evaluation of cellular mediated immunity in a normal adult population. 1977
1977 Cyclophosphamide, adriamycin, methotrexate + folinic acid rescue (CAMFAR) treatment of metastatic adenocarcinoma of the lung 1977
1977 Demonstration of Cryptococcus neoformans in a Stained Bone Marrow Specimen 1977
1977 Mucosal eosinophilic gastroenteritis with systemic involvement 1977
1976 Hematologic toxicity from bleomycin in advanced cancer patients. 1976

Principal Investigator On

  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2019 - 2024
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2019 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by MedImmune 2015 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2013 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2013 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2013 - 2019
  • Private Grant  awarded by STEM CENTRX 2014 - 2019
  • Private Grant  awarded by STEM CENTRX 2016 - 2018
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2017 - 2018
  • Private Grant  awarded by ELI LILLY AND COMPANY 2014 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2018
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2018
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2017 - 2018
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2018
  • Private Grant  awarded by HEAT BIOLOGICS 2015 - 2017
  • Private Grant  awarded by CLOVIS ONCOLOGY 2015 - 2017
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016 - 2017
  • Private Grant  awarded by ASCENTA THERAPEUTICS, INC. 2007 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2010 - 2016
  • Private Grant  awarded by Sanofi US Services Inc 2011 - 2016
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2016
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2016
  • Private Grant  awarded by THRESHOLD PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by EMD SERONO 2015
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2015
  • Clinical Studies of Bendamustine in Solid Tumors  awarded by NATIONAL COMPREHENSIVE CANCER NETWORK 2008 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2015
  • Private Grant  awarded by Genentech 2008 - 2015
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2014 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2015
  • Private Grant  awarded by Pfizer Pharmaceuticals 2010 - 2015
  • Private Grant  awarded by ASCENTA THERAPEUTICS, INC. 2009 - 2015
  • Private Grant  awarded by EMD SERONO 2014 - 2015
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2014 - 2015
  • Private Grant  awarded by AILERON THERAPEUTICS 2015
  • Private Grant  awarded by GlaxoSmithKline 2007 - 2014
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2011 - 2014
  • Private Grant  awarded by IMCLONE SYSTEMS, INC. 2010 - 2013
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2013
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2012 - 2013
  • Private Grant  awarded by ELI LILLY AND COMPANY 2011 - 2013
  • Private Grant  awarded by Pfizer Pharmaceuticals 2010 - 2012
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2007 - 2012
  • Private Grant  awarded by IMCLONE SYSTEMS, INC. 2005 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2010 - 2012
  • Private Grant  awarded by ASTRAZENECA INTERNATIONAL 2007 - 2012
  • Private Grant  awarded by Sanofi US Services Inc 2008 - 2011
  • Private Grant  awarded by GlaxoSmithKline 2006 - 2011
  • Private Grant  awarded by MORPHOTEK, INC. 2009 - 2011
  • Private Grant  awarded by Pfizer Pharmaceuticals 2006 - 2011
  • Private Grant  awarded by SUNESIS PHARMACEUTICALS, INC. 2007 - 2011
  • Private Grant  awarded by Pfizer Pharmaceuticals 2006 - 2011
  • Private Grant  awarded by Pfizer Pharmaceuticals 2006 - 2011
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2005 - 2011
  • Private Grant  awarded by MERCK & COMPANY, INC. 2006 - 2011
  • Investigator On

  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by MINNEAMRITA THERAPEUTICS, LLC 2018 - 2023
  • Private Grant  awarded by ROCHE TCRC, INC. 2018 - 2023
  • Private Grant  awarded by Sanofi US Services Inc 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by MERCK & COMPANY, INC. 2019 - 2023
  • Private Grant  awarded by SKYLINE BIOSCIENCES LLC 2019 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2022
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2019 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2022
  • Private Grant  awarded by MedImmune 2019 - 2022
  • Private Grant  awarded by NOVOCURE, INC. 2019 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2021
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Private Grant  awarded by IMAGINAB 2019 - 2021
  • Private Grant  awarded by ABLYNX NV 2016 - 2020
  • Private Grant  awarded by ELI LILLY AND COMPANY 2015 - 2020
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by AILERON THERAPEUTICS 2015 - 2020
  • Private Grant  awarded by EMD SERONO 2013 - 2019
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013 - 2017
  • Private Grant  awarded by DAIICHI SANKYO PHARMA DEVELOPMENT 2014 - 2016
  • Private Grant  awarded by SPECTRUM PHARMACEUTICALS, INC. 2013 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2015
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2014
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2014
  • Private Grant  awarded by STEM CENTRX 2014
  • Private Grant  awarded by ONCONOVA THERAPEUTICS 2013 - 2014
  • Education And Training

  • University Hospital of Puerto Rico, Internship 1970
  • University Hospital of Puerto Rico, Residency 1972
  • UAB Hospital, Postdoctoral Fellowship 1976
  • University of Puerto Rico, Postdoctoral Fellowship 1974
  • Full Name

  • Francisco Robert